Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY 4.0PLOS One

Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones

7 affiliations
  1. 1Faculty of Pharmaceutical Science, MSc Program in Research for Enterprise, Chulalongkorn University, Bangkok, Thailand
  2. 2Center of Excellence in Cellular Immunotherapy, Chulalongkorn University, Bangkok, Thailand
  3. 3Cell and Gene Therapy Manufacturing Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
  4. 4Faculty of Medicine, Center of Excellence in Systems Biology, Chulalongkorn University, Bangkok, Thailand
  5. 5Thailand Hub of Talents in Cancer Immunotherapy, Bangkok, Thailand
  6. 6Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
  7. 7Department of Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell malignancies, but relapse after CD19-directed therapy remains a major challenge, often because of loss or downregulation of CD19 expression. CD22 is an attractive alternative target because it is expressed on malignant B cells, including in many cases of CD19-negative disease. In this study, we generated and characterized novel anti-CD22 monoclonal antibody–derived CAR constructs for in vitro evaluation. Four anti-CD22 monoclonal antibody clones were initially screened, and two clones, 24A7G6 and 29H9C8, were selected for CAR development based on their favorable binding and CAR surface expression profiles. Second-generation CAR constructs containing either a 4−1BB or CD28 costimulatory domain were generated and introduced into primary human T cells. The resulting CAR T cells were evaluated for expansion, immunophenotype, activation and inhibitory marker expression, cytokine secretion, short-term cytotoxicity, long-term co-culture activity, and sequential tumor rechallenge against CD22-positive Raji and Nalm-6 cells and CD22-negative K562 cells. Both 24A7G6- and 29H9C8-derived CAR T cells expanded efficiently, showed predominant CD8 + populations with naïve and central memory phenotypes, and mediated potent antigen-specific cytotoxicity against CD22-positive target cells, while showing no activity against CD22-negative cells. Following antigen stimulation, CAR T cells upregulated activation markers and showed modest increases in inhibitory receptors. In long-term co-culture and sequential rechallenge assays, all constructs retained antitumor activity under prolonged antigen exposure. Notably, the 24A7G6-CD28 CAR demonstrated enhanced sustained tumor control compared with the corresponding 4−1BB construct in extended assays, whereas short-term cytotoxicity was broadly comparable across constructs. These findings show that the newly generated 24A7G6 and 29H9C8 scFvs can function as effective targeting domains for CD22-directed CAR T-cell development and provide an in vitro basis for prioritizing lead constructs for further preclinical evaluation.

Related

  1. Chimeric archaeal BHB-human pre-tRNA scaffold HARBOR system enables versatile production of functional circular RNA modalities
    S.-M. Cao, X. Feng, J. T.-C. Zhang +4
    bioRxivPreprintAll rights reservedFull textMolecular biology & gene regulationbioRxiv
  2. Integrative discovery and functional dependency mapping uncover essential chimeric RNAs in the active transcriptome
    Samir Lalani, Samuel Haddox, Kendall Bromley +11
    Science AdvancesPeer-reviewedCC BYFull textMolecular biology & gene regulationOncologySci. Adv.CrossrefEurope PMCEurope PMC+1
  3. The generation and characterization of CTRP9-CreERT2 knock-in mice for targeting endothelial cell muscle and adipose tissues
    Qingye Wang, Zhangxi Fu, Haizhen Wang +8
    Cell regeneration (London, England)Peer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationEurope PMC
  4. Generation and characterization of three human induced pluripotent stem cell lines from patients with Duchenne muscular dystrophy
    Hamel Mahiou, Benjamin Marande, Lina El Kassar +15
    Stem Cell ResearchPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationHAL
  5. Strategies for Overcoming the Purification Challenges of Meis1 and HoxA9 and Their Functional Characterization
    I. A. Olaosebikan, K. C. Courtney, H. Karatas Bristow
    bioRxivPreprintAll rights reservedFull textGeneral biochemistrybioRxiv
BibTeX
@article{ruengdej2026generation,
  title = {{Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones}},
  author = {Wipawadee Ruengdej and Vichaya Chuthaphakdikun and Sirirut Jewmoung and Nithidol Sakunrangsit and Chatikorn Boonkrai and Trairak Pisitkun and Supannikar Tawinwung and Koramit Suppipat},
  journal = {PLOS One},
  year = {2026},
  month = nov,
  doi = {10.1371/journal.pone.0362221},
  url = {https://doi.org/10.1371/journal.pone.0362221},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones
AU  - Wipawadee Ruengdej
AU  - Vichaya Chuthaphakdikun
AU  - Sirirut Jewmoung
AU  - Nithidol Sakunrangsit
AU  - Chatikorn Boonkrai
AU  - Trairak Pisitkun
AU  - Supannikar Tawinwung
AU  - Koramit Suppipat
PY  - 2026
DA  - 2026/11/12
JO  - PLOS One
DO  - 10.1371/journal.pone.0362221
UR  - https://doi.org/10.1371/journal.pone.0362221
AB  - Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell malignancies, but relapse after CD19-directed therapy remains a major challenge, often because of loss or downregulation of CD19 expression. CD22 is an attractive alternative target because it is expressed on malignant B cells, including in many cases of CD19-negative disease. In this study, we generated and characterized novel anti-CD22 monoclonal antibody–derived CAR constructs for in vitro evaluation. Four anti-CD22 monoclonal antibody clones were initially screened, and two clones, 24A7G6 and 29H9C8, were selected for CAR development based on their favorable binding and CAR surface expression profiles. Second-generation CAR constructs containing either a 4−1BB or CD28 costimulatory domain were generated and introduced into primary human T cells. The resulting CAR T cells were evaluated for expansion, immunophenotype, activation and inhibitory marker expression, cytokine secretion, short-term cytotoxicity, long-term co-culture activity, and sequential tumor rechallenge against CD22-positive Raji and Nalm-6 cells and CD22-negative K562 cells. Both 24A7G6- and 29H9C8-derived CAR T cells expanded efficiently, showed predominant CD8 + populations with naïve and central memory phenotypes, and mediated potent antigen-specific cytotoxicity against CD22-positive target cells, while showing no activity against CD22-negative cells. Following antigen stimulation, CAR T cells upregulated activation markers and showed modest increases in inhibitory receptors. In long-term co-culture and sequential rechallenge assays, all constructs retained antitumor activity under prolonged antigen exposure. Notably, the 24A7G6-CD28 CAR demonstrated enhanced sustained tumor control compared with the corresponding 4−1BB construct in extended assays, whereas short-term cytotoxicity was broadly comparable across constructs. These findings show that the newly generated 24A7G6 and 29H9C8 scFvs can function as effective targeting domains for CD22-directed CAR T-cell development and provide an in vitro basis for prioritizing lead constructs for further preclinical evaluation.
SN  - 1932-6203
ER  -